Bausch & Lomb Corp acquired XIIDRA

Bausch & Lomb Corp -> XIIDRA · $2.5 billion

“We expect to quickly take a leading position in the growing prescription dry eye category with the XIIDRA acquisition and MIEBO launch and, importantly, help the millions of patients not currently receiving adequate treatment for dry eye disease ,” said Brent